Home / News / India News / Article /
Covid-19 antiviral drug Molnupiravir has major safety concerns: ICMR chief
Updated On: 05 January, 2022 10:36 PM IST | New Delhi | PTI
ICMR chief Dr Balram Bhargava said the US has approved it based on only 1,433 patients in which three per cent reduction was observed in symptoms in patients with mild to moderate disease
Listen to this article :
DG ICMR Balram Bhargava (right) addresses a press briefing on the actions taken, preparedness and updates on Covid-19, in New Delhi. Pic/PTI
ICMR Chief Dr Balram Bhargava said that Covid antiviral drug Molnupiravir has major safety concerns and has not been included in the national protocol for the treatment of coronavirus.
During a press briefing, he said the World Health Organisation and the UK have not included it for treatment. "We have to remember that this drug has major safety concerns. It can cause teratogenicity, mutagenicity and it can also cause cartilage damage and can also be damaging to muscles also. Contraception will have to be done for three months for male and female if this drug is given because the child born could be problematic due to teratogenic influence," he told reporters.
Read Next Story
Trending Stories
Latest Photos
Latest Videos
Latest Web Stories
ADVERTISEMENT
Mid-Day Fast
ADVERTISEMENT
ADVERTISEMENT